Kaftrio 75 mg/50 mg/100 mg film-coated tablets
Sponsors
Vertex Pharmaceuticals Inc., IRCCS Istituto Giannina Gaslini
Conditions
Cystic Fibrosis
Phase 3
A Phase 3 Open-label Study Evaluating the Long term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 2 Years and Older
CompletedCTIS2024-515606-90-00
Start: 2022-04-01End: 2026-01-14Target: 3Updated: 2025-08-19
A Phase 3 Open-label Study Evaluating the Longterm Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects With Non-F508del CFTR Genotypes
Active, not recruitingCTIS2024-515637-14-00
Start: 2022-11-08Target: 295Updated: 2025-11-14